Skip to main content

Certara, Thomson Reuters Ink Data Access Agreement


Certara said this week that it is partnering with Thomson Reuters to provide customers of its D360 software solution with access to content contained in Thomson Reuters' Cortellis for Informatics system.

The D360 solution provides tools for pharmaceutical companies to query, analyze, and visualize drug discovery and development data. Cortellis for Informatics provides information such as published experimental pharmacology, pharmacokinetic, and pharmacodynamic results; clinical trial protocols and outcomes; competitive intelligence; patent information; and pharma company press releases and presentations.

Among other benefits, the partnership will "enable our mutual customers to integrate Thomson Reuters' authoritative content with other proprietary and public data that they have integrated via the D360 platform," according to Joseph Donahue, senior vice president at Thomson Reuters.

It will also provide D360's users with "data views that present curated public data alongside a company's internal proprietary data," Jonathan Feldmann, vice president, scientific informatics at Certara, said in a statement.

The financial details of the agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.